Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)
- 31 January 2010
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 46 (1), 72-83
- https://doi.org/10.1016/j.ejca.2009.09.022
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignanciesNature Clinical Practice Oncology, 2008
- Significant clinical benefit of first‐line palliative chemotherapy in advanced soft‐tissue sarcomaCancer, 2008
- The Pharmacologic Basis of Ifosfamide Use in Adult Patients with Advanced Soft Tissue SarcomasThe Oncologist, 2007
- Differential sensitivity of liposarcoma subtypes to chemotherapyEuropean Journal of Cancer, 2005
- Using Single-Agent Therapy in Adult Patients with Advanced Soft Tissue Sarcoma Can Still Be Considered Standard CareThe Oncologist, 2005
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Changing concepts in the pathological basis of soft tissue and bone sarcoma treatmentEuropean Journal of Cancer, 2004
- Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas. The Experience of the EORTC Soft Tissue and Bone Sarcoma GroupSarcoma, 2000
- Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcomaEuropean Journal of Cancer and Clinical Oncology, 1990
- Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC soft tissue and bone sarcoma groupEuropean Journal of Cancer and Clinical Oncology, 1987